Globus Medical shows strong growth amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Source: Fool
Globus Medical Inc (GMED) has seen a price increase of 5.32% as it reaches a 5-day high, contrasting with the broader market's downturn.
The company has achieved an impressive annual revenue growth of 30.3% over the past five years, alongside a 22.2% annual increase in earnings per share, showcasing its strong competitive position in the spine and neurosurgery markets. This strong performance stands out particularly as the Nasdaq-100 (QQQ) is down 1.62% and the S&P 500 (SPY) is down 0.58%, indicating a sector rotation where GMED is thriving despite overall market weakness.
This resilience in performance suggests that Globus Medical is well-positioned to continue its growth trajectory, even in challenging economic conditions, making it an attractive option for investors looking for stability in mid-cap stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 75.420
Low
87.00
Averages
101.00
High
114.00
Current: 75.420
Low
87.00
Averages
101.00
High
114.00
About GMED
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. It separates its products and services into two major categories: Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Resmed's Acquisition Fuels Growth in Residential Care Software Segment
- Acquisition-Driven Growth: Resmed's strategic acquisitions, including MEDIFOX DAN, have successfully expanded its Residential Care Software segment, which is expected to continue supporting growth in the coming quarters and enhance synergies within its Sleep and Breathing Health franchise.
- Mask Innovation and Resupply: In Q3 of fiscal 2026, Resmed's mask and other sales increased by 14%, driven by new product designs and resupply strategies, which not only improved patient comfort but also supported customer retention in long-term therapy.
- Enhanced Financial Flexibility: As of Q3 fiscal 2026, Resmed reported $1.66 billion in cash, with short-term debt at $260 million and long-term debt at $404 million, resulting in a debt-to-capital ratio improvement to 5.9%, indicating relatively low financial risk.
- Macroeconomic Challenges: Despite Resmed's solid financial performance, it faces challenges from macroeconomic pressures and intense competition, which could impact demand and operating costs, potentially leading to negative effects on the company's overall performance.
See More
Mid-Cap Stock Investment Opportunities Analysis
- DocuSign's Weak Performance: DocuSign (DOCU), with a market cap of $9.9 billion, has shown disappointing average ARR growth of only 8.8% over the past year, indicating challenges in securing long-term deals and renewals, which complicates justifying sales and marketing investments that could enhance revenue growth potential.
- Globus Medical's Strong Growth: Globus Medical (GMED), valued at $10.86 billion, has achieved an impressive annual revenue growth of 30.3% over the past five years, demonstrating resilience in various global economic conditions, while its earnings per share have increased by 22.2% annually, showcasing its strong competitive position in the spine and neurosurgery markets.
- RB Global's Outstanding Market Performance: RB Global (RBA), with a market cap of $19.66 billion, has recorded an annual revenue growth of 26.9% over the past five years, with an adjusted operating margin expansion of 2.5 percentage points, reflecting its scaling efficiency, and its earnings per share have grown by 19.1% annually, significantly outpacing its peers.
- Mid-Cap Investment Outlook: Despite facing competition from larger firms, mid-cap stocks present unique investment opportunities, and StockStory aids investors in identifying companies with solid fundamentals, enabling them to capitalize on market opportunities, particularly in the current economic landscape.
See More
Purcell & Lefkowitz Investigates Globus Medical for Shareholder Rights
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Globus Medical (NYSE:GMED) to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder interests.
- Shareholder Rights Focus: The investigation aims to protect the rights of Globus Medical shareholders, with the law firm offering free consultations to help shareholders understand their rights and options, thereby enhancing confidence in corporate governance.
- Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating its professionalism and commitment to safeguarding shareholder rights.
- Contact Information Provided: Shareholders seeking more information can directly contact the law firm via email or phone to ensure timely legal support, reflecting the firm's emphasis on client service.
See More
Jim Cramer Expresses Negative Views on Multiple Companies
- Purecycle Technologies Struggles: Jim Cramer highlights that Purecycle Technologies has almost no revenue and is losing a fortune, suggesting investors should avoid this stock, indicating its unfavorable market perception.
- High Risk for Energy Vault Holdings: Cramer describes Energy Vault Holdings as a pure speculative stock that is also losing a fortune, implying its investment value is extremely low and investors should exercise caution.
- Everspin Technologies Overvalued: While Everspin Technologies is profitable, Cramer warns that its price-to-earnings ratio is at 90 times, advising investors to be careful, suggesting that market expectations for its future growth may be overly optimistic.
- Challenges for Rocket Companies: Cramer expresses a negative view on Rocket Companies, stating that even if Kevin Warsh might cut rates, the rising oil prices causing inflation make such cuts unlikely, indicating significant pressure on the company's future prospects.
See More
Globus Medical Q1 Earnings Beat Expectations but Stock Plummets
- Earnings Beat: Globus Medical reported an adjusted EPS of $1.12 for Q1, exceeding expectations by $0.20, indicating strong performance in the medical device sector, although the stock fell due to negative market reactions.
- Significant Revenue Growth: Total revenue reached $759.9 million in Q1, a 27% year-over-year increase, with $82.7 million coming from Nevro sales, demonstrating successful acquisition integration and enhancing market competitiveness.
- Substantial Net Income Increase: GAAP net income surged 64.7% to $124.3 million, reflecting ongoing growth in the U.S. spine business, particularly with a third consecutive quarter of 10% growth, showcasing the stability and growth potential of its operations.
- Optimistic Full-Year Guidance: Globus raised its full-year GAAP EPS guidance to $4.70 to $4.80 while reaffirming revenue guidance of $3.18 billion to $3.22 billion, indicating confidence in future performance despite recent stock price declines.
See More
Globus Medical Reports Strong Q1 2026 Earnings with Increased EPS Guidance
- Significant Revenue Growth: Globus Medical reported Q1 revenue of $759.9 million, reflecting a strong focus on expanding market share, which is expected to positively impact full-year results.
- Improved Profitability: The company achieved a non-GAAP earnings per share of $1.12 in Q1, exceeding expectations by $0.20, indicating successful operational efficiency and cost control, thereby enhancing investor confidence.
- Business Model Shift: The company is gradually shifting its robotics business towards lease and rental models, which is expected to drive future revenue growth, although short-term revenue volatility may pose challenges.
- Optimistic Outlook: Globus Medical reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP EPS forecast to $4.70 to $4.80, demonstrating management's confidence in future growth.
See More
Resmed's Acquisition Fuels Growth in Residential Care Software Segment
- Acquisition-Driven Growth: Resmed's strategic acquisitions, including MEDIFOX DAN, have successfully expanded its Residential Care Software segment, which is expected to continue supporting growth in the coming quarters and enhance synergies within its Sleep and Breathing Health franchise.
- Mask Innovation and Resupply: In Q3 of fiscal 2026, Resmed's mask and other sales increased by 14%, driven by new product designs and resupply strategies, which not only improved patient comfort but also supported customer retention in long-term therapy.
- Enhanced Financial Flexibility: As of Q3 fiscal 2026, Resmed reported $1.66 billion in cash, with short-term debt at $260 million and long-term debt at $404 million, resulting in a debt-to-capital ratio improvement to 5.9%, indicating relatively low financial risk.
- Macroeconomic Challenges: Despite Resmed's solid financial performance, it faces challenges from macroeconomic pressures and intense competition, which could impact demand and operating costs, potentially leading to negative effects on the company's overall performance.
See More
Mid-Cap Stock Investment Opportunities Analysis
- DocuSign's Weak Performance: DocuSign (DOCU), with a market cap of $9.9 billion, has shown disappointing average ARR growth of only 8.8% over the past year, indicating challenges in securing long-term deals and renewals, which complicates justifying sales and marketing investments that could enhance revenue growth potential.
- Globus Medical's Strong Growth: Globus Medical (GMED), valued at $10.86 billion, has achieved an impressive annual revenue growth of 30.3% over the past five years, demonstrating resilience in various global economic conditions, while its earnings per share have increased by 22.2% annually, showcasing its strong competitive position in the spine and neurosurgery markets.
- RB Global's Outstanding Market Performance: RB Global (RBA), with a market cap of $19.66 billion, has recorded an annual revenue growth of 26.9% over the past five years, with an adjusted operating margin expansion of 2.5 percentage points, reflecting its scaling efficiency, and its earnings per share have grown by 19.1% annually, significantly outpacing its peers.
- Mid-Cap Investment Outlook: Despite facing competition from larger firms, mid-cap stocks present unique investment opportunities, and StockStory aids investors in identifying companies with solid fundamentals, enabling them to capitalize on market opportunities, particularly in the current economic landscape.
See More
Purcell & Lefkowitz Investigates Globus Medical for Shareholder Rights
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Globus Medical (NYSE:GMED) to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder interests.
- Shareholder Rights Focus: The investigation aims to protect the rights of Globus Medical shareholders, with the law firm offering free consultations to help shareholders understand their rights and options, thereby enhancing confidence in corporate governance.
- Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating its professionalism and commitment to safeguarding shareholder rights.
- Contact Information Provided: Shareholders seeking more information can directly contact the law firm via email or phone to ensure timely legal support, reflecting the firm's emphasis on client service.
See More
Jim Cramer Expresses Negative Views on Multiple Companies
- Purecycle Technologies Struggles: Jim Cramer highlights that Purecycle Technologies has almost no revenue and is losing a fortune, suggesting investors should avoid this stock, indicating its unfavorable market perception.
- High Risk for Energy Vault Holdings: Cramer describes Energy Vault Holdings as a pure speculative stock that is also losing a fortune, implying its investment value is extremely low and investors should exercise caution.
- Everspin Technologies Overvalued: While Everspin Technologies is profitable, Cramer warns that its price-to-earnings ratio is at 90 times, advising investors to be careful, suggesting that market expectations for its future growth may be overly optimistic.
- Challenges for Rocket Companies: Cramer expresses a negative view on Rocket Companies, stating that even if Kevin Warsh might cut rates, the rising oil prices causing inflation make such cuts unlikely, indicating significant pressure on the company's future prospects.
See More
Globus Medical Q1 Earnings Beat Expectations but Stock Plummets
- Earnings Beat: Globus Medical reported an adjusted EPS of $1.12 for Q1, exceeding expectations by $0.20, indicating strong performance in the medical device sector, although the stock fell due to negative market reactions.
- Significant Revenue Growth: Total revenue reached $759.9 million in Q1, a 27% year-over-year increase, with $82.7 million coming from Nevro sales, demonstrating successful acquisition integration and enhancing market competitiveness.
- Substantial Net Income Increase: GAAP net income surged 64.7% to $124.3 million, reflecting ongoing growth in the U.S. spine business, particularly with a third consecutive quarter of 10% growth, showcasing the stability and growth potential of its operations.
- Optimistic Full-Year Guidance: Globus raised its full-year GAAP EPS guidance to $4.70 to $4.80 while reaffirming revenue guidance of $3.18 billion to $3.22 billion, indicating confidence in future performance despite recent stock price declines.
See More
Globus Medical Reports Strong Q1 2026 Earnings with Increased EPS Guidance
- Significant Revenue Growth: Globus Medical reported Q1 revenue of $759.9 million, reflecting a strong focus on expanding market share, which is expected to positively impact full-year results.
- Improved Profitability: The company achieved a non-GAAP earnings per share of $1.12 in Q1, exceeding expectations by $0.20, indicating successful operational efficiency and cost control, thereby enhancing investor confidence.
- Business Model Shift: The company is gradually shifting its robotics business towards lease and rental models, which is expected to drive future revenue growth, although short-term revenue volatility may pose challenges.
- Optimistic Outlook: Globus Medical reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP EPS forecast to $4.70 to $4.80, demonstrating management's confidence in future growth.
See More
